An interesting provision in the Senate bill calls for the government to determine how much money the healthcare system saves
by allowing FOBs to come to market. The Department of the Treasury will study the market and establish a Biological Product
Savings Fund to channel those savings to other public health programs. A lot of interest groups have predicted huge gains
from FOBs, and it will be interesting to see the results.
Jill Wechsler is Pharmaceutical Executive's Washington correspondent. She can be reached at firstname.lastname@example.org